Skip to main content
Venus Medtech (Hangzhou) Inc. logo

Venus Medtech (Hangzhou) Inc. — Investor Relations & Filings

Ticker · 2500 ISIN · CNE100003PJ8 HKEX Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2025-02-21 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2500

About Venus Medtech (Hangzhou) Inc.

http://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc. is an innovation-driven medical device company specializing in the research, development, manufacturing, and commercialization of transcatheter solutions for structural heart diseases. The company focuses on bioprosthetic heart valves, establishing a comprehensive pipeline that addresses aortic, pulmonary, mitral, and tricuspid valve diseases. Its product portfolio includes transcatheter aortic valve replacement (TAVR) solutions, and it is committed to addressing unmet demand in TPVR and TMVR. The company also develops solutions for hypertension, such as renal artery denervation ablation, and related surgical accessory products. Its products are commercialized globally, reaching over 60 countries and regions across Asia, Europe, and the Americas.

Recent filings

Filing Released Lang Actions
(1) THE FIFTH QUARTERLY UPDATE ON RESUMPTION PROGRESS&#x3b; AND (2) CONTINUED SUSPENSION OF TRADING
Regulatory Filings Classification · 85% confidence The document is an official announcement by a Hong Kong listed company under the Listing Rules, providing a quarterly update on resumption progress and continued suspension of trading. It is not an earnings release, financial report, dividend notice, or M&A announcement, nor is it reporting board changes or share transactions. It does not attach a report for publication; instead, it itself is a regulatory disclosure about compliance and resumption conditions. Therefore, it falls into the general regulatory announcement category (RNS).
2025-02-21 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 January 2025
Regulatory Filings Classification · 95% confidence The document is a routine monthly return (Form FF301) filed to the Hong Kong Stock Exchange under Listing Rule Chapter 19B, detailing movements in share capital, issued shares, share options, treasury shares, etc. It is not announcing a specific financing event or issuing new capital per se, nor is it an earnings release, annual or interim report, shareholder meeting material, or legal proceeding. It is a regulatory compliance filing without a more specific category, so it falls under the general “Regulatory Filings” (RNS) category.
2025-02-05 English
(1) UPDATE ON HISTORICAL USE OF PROCEEDS DISCLOSURE&#x3b; AND (2) CHANGE IN USE OF PROCEEDS FROM THE INITIAL GLOBAL OFFERING
Capital/Financing Update Classification · 90% confidence The document is an exchange announcement providing a detailed update on the historical and revised use of net proceeds from the company’s Initial Global Offering and subsequent placings. It is clearly focused on the company’s fundraising activities and how the capital raised has been allocated and reallocated, which matches the description for a Capital/Financing Update. Therefore, the correct filing type is CAP.
2025-01-12 English
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 December 2024
Regulatory Filings Classification · 90% confidence The document is a standardized monthly return (Form FF301) filed to Hong Kong Exchanges and Clearing Limited under the Exchange Listing Rules, detailing movements in authorized and issued share capital and treasury shares for the month ended 31 December 2024. It is not an earnings release, debt notice, proxy statement, or capital markets offering; rather it is a routine regulatory submission under listing rules. Therefore it falls under the fallback category of Regulatory Filings (RNS).
2025-01-06 English
TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS
Governance Information Classification · 88% confidence The document is the “Terms of Reference of the Audit Committee of the Board of Directors,” specifying composition, duties, and procedures of a board committee. This is clearly an internal governance charter rather than a financial report, announcement of results, or transaction notice. It falls under Governance Information (CGR).
2024-12-05 English
TERMS OF REFERENCE OF THE REMUNERATION AND ASSESSMENT COMMITTEE OF THE BOARD OF DIRECTORS
Governance Information Classification · 92% confidence The document is a formal charter outlining the composition, duties, and procedures of the Remuneration and Assessment Committee of the Board. It defines internal governance rules, committee structure, responsibilities, and decision‐making processes rather than reporting financial results or announcing specific transactions. This fits the definition of a corporate governance information report (Governance Information).
2024-12-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.